EN DE
Watch Sight Sciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sight Sciences Inc (SGHT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Sight Sciences Inc stock $7.38, price $10.59, that is 30.3% below the price, quality 51 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US82657M1053

SS Sight Sciences Inc logo Thin data Nov 17, 2026

Sight Sciences Inc

SGHT · US

Expensive (fair value 30% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Revenue last quarter +25% vs. a year ago. 
Quality 51/100 
Expensive Growth (revenue 5y +22.9 %/yr in USD) 
Moderate debt 
Insiders bought $68,808 (6M) · sold $1.2M 
Fair value $7.38 · Overvalued 
Loss-making · -32.1% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 9/100
Thin data 
Estimate
Watch Sight Sciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$38.38 $1.29 Fair Value $7.38 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $1.29 – $38.38 · fair‑value band $5.53 – $9.22 · the $10.59 price screens above the $7.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Sight Sciences in your weekly email

Every Wednesday you see whether Sight Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.

Show moreShow less

The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.

The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists.

It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Stock analysis

Sight Sciences Inc (SGHT) currently trades at $10.59, while our estimate is $7.38, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.53 (bear) to $9.22 (bull), the price of $10.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Sight Sciences Inc reported revenue of $77.4M in FY2025 versus $49.0M in FY2021, a compound +12.1%/yr. Reported net income was −$38.4M in FY2025.

Key figures

Market cap $577M Small · P/S ratio 6.92 · EPS (TTM) $−0.5200 · Net margin −32.1% · Return on equity −50.1% · Return on assets (EBIT) −31.9% (5-year average) · Operating margin −24.6% · Revenue (TTM) $88.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 4% below its 52-week high and 207% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −30%, SGHT screens richer than that median.

Fair Value

Bear $5.53 Fair Value $7.38 Bull $9.22
Price $10.59 · Downside -30.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 29
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 81
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 92
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $68,808, on Jun 10, 2026. Over the same period, 6 people sold shares worth $1.2M.

  • SaleJames RodbergChief Financial Officer6× since Dec 2, 2025: 31,474 shares, avg. $6.46$203,459Oct 2, 2026
  • SaleAlison BauerleinChief Operating Officer5× since Jan 5, 2026: 108,589 shares, avg. $6.13$665,828Oct 2, 2026
  • SaleBrenton TaylorEVP, Operations & R&D5× since Nov 17, 2025: 23,723 shares, avg. $6.69$158,822Oct 2, 2026
  • SalePaul BadawiPresident and CEO, Director, 10% owner5× since Jan 2, 2026: 147,169 shares, avg. $6.50$957,219Oct 1, 2026
  • SaleDavid BadawiChief Technology Officer, Director5× since Jan 2, 2026: 37,879 shares, avg. $6.47$245,016Oct 1, 2026
  • SaleJeremy B. HaydenChief Legal Officer5× since Nov 25, 2025: 88,822 shares, avg. $6.87$609,900Jul 6, 202610b5-1 plan
  • BuyStaffan EncrantzDirector, 10% owner2× since Dec 16, 2025: 28,058 shares, avg. $6.59$184,799Jun 10, 2026

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−116.5% (2020) → −48.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SGHT screens overvalued: fair value 30% below the price. Compare with Abbott Laboratories, →

Compare Sight Sciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside −30.3% · Below median
Profitability
Return on assets −33.3% · Bottom 25%
Net margin (12 months) −32.1% · Bottom 25%
Operating margin (12 months) −24.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 25.2% · Top 25%
Balance sheet
Debt / equity 0.71× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 9.03× · Priciest 25%
P/S (12 months) 6.53× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)64 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs SGHT
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs SGHT
Stryker Corporation SYK $310.72 $340.60 +10% vs SGHT
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs SGHT
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs SGHT
Siemens Healthineers AG SHL €44.00 €34.51 −22% vs SGHT
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs SGHT
Medtronic plc MDT $102.88 $74.89 −27% vs SGHT
Abbott Laboratories, ABT $107.45 $75.28 −30% vs SGHT
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs SGHT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sight Sciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sight Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/SGHT

Frequently asked questions

Is Sight Sciences Inc (SGHT) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $7.38 versus a price of $10.59, about 30% lower (overvalued).
What is the fair value of SGHT?
Our estimate for Sight Sciences Inc is $7.38 (as of Nov 17, 2026), built from audited fundamentals. The current price: $10.59.
What is the quality score of SGHT?
Sight Sciences Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sight Sciences Inc (SGHT)?
Our calculated price target is the estimate of $7.38 (as of Nov 17, 2026). Cautious scenario $5.53, optimistic scenario $9.22. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sight Sciences Inc stock forecast for 2026?
Our estimate puts fair value at $7.38, about 30% lower versus a price of $10.59 (overvalued). Cautious scenario $5.53, optimistic scenario $9.22. The calculation is refreshed regularly with new filings.
What is the revenue of Sight Sciences Inc (SGHT)?
Sight Sciences Inc reported trailing-twelve-month revenue of about $88.4M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Sight Sciences Inc (SGHT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sight Sciences Inc it is $7.38 per share (as of Nov 17, 2026), against a price of $10.59.
Is Sight Sciences Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SGHT trades above its calculated fair value: price $10.59, fair value $7.38, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SGHT?
No. The price is what the market pays today ($10.59); the fair value is what the company's own numbers justify ($7.38). For Sight Sciences Inc the two are $3.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sight Sciences Inc worth?
The market values Sight Sciences Inc at about $577M (market capitalisation, as of Nov 17, 2026). Per share that is $10.59; our models calculate a fair value of $7.38 per share.
What do the bullish and bearish scenarios say about SGHT?
Our models span a range for Sight Sciences Inc: cautious scenario $5.53, base $7.38, optimistic $9.22 per share (as of Nov 17, 2026, price $10.59). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sight Sciences Inc (SGHT)?
Balance-sheet figures for Sight Sciences Inc (as of Nov 17, 2026): return on equity −50.1%, debt of 0.71 per unit of equity (balance sheet 30 Sep 2026). They feed the Quality Score of 51/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is SGHT from its 52-week high?
Sight Sciences Inc trades at $10.59, about 4% below its 52-week high of $11.01 and 207% above the low of $3.45 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $7.38 is for.
Which stocks are comparable to Sight Sciences Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sight Sciences Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $10.59, calculated fair value $7.38 (−30%), Quality Score 51/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Sight Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sight Sciences Inc (SGHT)?
The closing price on Nov 16, 2026 was $10.59. Our estimate is $7.38, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sight Sciences Inc right now?
The price sits above even our optimistic bull case ($9.22). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sight Sciences Inc

How large is the market capitalisation of Sight Sciences Inc (SGHT)?
The market capitalisation of Sight Sciences Inc is $577M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sight Sciences Inc (SGHT)?
The price-to-sales ratio of Sight Sciences Inc is 6.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sight Sciences Inc (SGHT)?
Earnings per share at Sight Sciences Inc are $−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sight Sciences Inc (SGHT)?
The net margin of Sight Sciences Inc is −32.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sight Sciences Inc (SGHT)?
The return on equity (ROE) of Sight Sciences Inc is −50.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sight Sciences Inc (SGHT)?
On an EBIT basis the return on assets of Sight Sciences Inc is −31.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sight Sciences Inc (SGHT)?
The operating margin of Sight Sciences Inc is −24.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sight Sciences Inc (SGHT)?
Revenue at Sight Sciences Inc is growing 25.2% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sight Sciences Inc (SGHT) generate?
The free cash flow of Sight Sciences Inc is −$29.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sight Sciences Inc (SGHT) hold?
Sight Sciences Inc holds more cash than debt, $35.3M net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sight Sciences Inc in the live analysis

One click puts Sight Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.